ASTROPAY
4.8.2022 10:02:11 CEST | Business Wire | Press release
AstroPay, the payment solution of choice for millions of users globally, today announced the appointment of Fayyaz Ansari as Chief Financial Officer.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220804005257/en/
Having worked in finance for over 20 years, Fayyaz brings with him a deep understanding of the global payments industry. Prior to joining AstroPay, he was working at Skrill, NETELLER & Income Access (part of Paysafe group Plc) as CFO of their digital wallet division and board member of their regulated entities. He will be based in the UK with responsibility for overseeing all aspects of AstroPay’s global financial management and activities.
Fayyaz’s extensive leadership experience includes controllership, treasury, financial planning and analysis, tax restructuring, corporate finance, performance management, M&A and strategic planning. He also managed other aspects of the finance function which includes banking, investments, financial systems and was involved in fundraising as well as coordinating efforts for an exit via a trade sale/ IPO. Fayyaz started his career as an auditor and prior to joining Skrill, he worked for PricewaterhouseCoopers LLP. He is a chartered accountant and holds an MBA from Warwick Business School in the UK.
Mikael Lijtenstein, CEO of AstroPay, commented : “I am delighted to welcome Fayyaz to AstroPay where he will undoubtedly make an immediate impact as we aim to become the world’s leading payments platform. His wealth of experience will be essential in implementing our strategic plans to accelerate growth and position AstroPay for the future. Fayyaz and the team will contribute to our mission of providing financial freedom to millions of people worldwide. He is an excellent addition to the AstroPay team and I look forward to working with him in our journey.”
Fayyaz Ansari, CFO of AstroPay added : “I’m thrilled to have the opportunity to join AstroPay as the next step in my career. I am excited about working with a team that is passionate about the business, has a clear strategy and always puts customers’ needs first. With its commitment to global expansion, a strong business model, a focus on diversity and proud history, AstroPay is well positioned for extraordinary growth and impact. I believe the company’s unique value proposition and strong foundation will allow the business to grow and execute its vision of making payments much more accessible to customers around the world.”
Notes to editors:
About AstroPay
Founded in 2009, AstroPay is a pioneer in global payment solutions. It is the digital wallet of choice for millions of customers in Asia, Africa, Latin America, and Europe who want to make online purchases on international sites, and it also aims to help merchants access markets more easily and securely.
AstroPay has offices in the UK and Latin America, with millions of users, hundreds of merchants, and more than 200 payment methods available globally. It has extensive experience in handling the specificities of different markets, offering an efficient solution to all its customers: merchants, end users, and business partners.
Visit www.astropay.com .
View source version on businesswire.com: https://www.businesswire.com/news/home/20220804005257/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Angelini Pharma and Quiver Bioscience Announce Strategic Research Collaboration and Licensing Agreement to Discover and Advance Novel Therapeutics for Genetic Epilepsies23.2.2026 14:08:00 CET | Press release
Angelini Pharma secures exclusive global license rights to future identified drug targets Quiver receives undisclosed advance payment and is eligible for future milestone-dependent payments and royalties Collaboration further expands Angelini Pharma’s focus on brain health, building on its deep therapeutic expertise and drug development experience Angelini Pharma, part of the privately owned Angelini Industries, and Quiver Bioscience (“Quiver”), a discovery technology and therapeutics company advancing programs for the treatment of central nervous system (CNS) disorders, announced today that they have entered into a collaboration and licensing agreement to advance novel therapeutics for genetic epilepsies. The collaboration brings together Quiver’s unique drug discovery capabilities, data assets, and AI models with Angelini Pharma’s established expertise in brain health and epilepsy drug development. This press release features multimedia. View the full release here: https://www.busine
Armis Achieves U.S. Department of Defense Impact Level 5 Authorization23.2.2026 14:00:00 CET | Press release
DoD customers can now leverage Armis Centrix™ with enhanced security controls and connectivity Armis, the cyber exposure management & security company, today announced that it has achieved authorization from the U.S. DoD’s Defense Information Systems Agency (DISA) to operate at an Impact Level 5 (IL5). This means that Armis has met strict requirements to manage and secure the DoD’s critical infrastructure, including Controlled Unclassified Information (CUI) systems. “We are committed to helping Federal agencies like the Department of Defense address their toughest cybersecurity challenges,” said Alex Mosher, President and CRO at Armis. “Achieving DISA IL5 authorization is an important milestone for Armis as we continue to support DoD customers in safeguarding critical systems, sensitive data and national security infrastructure from evolving cyber threats.” Armis empowers Federal agencies to build and optimize comprehensive cybersecurity programs with Armis Centrix™, the FedRAMP and DI
IQM, a Global Leader for Quantum Computing, to Become the First Listed European Quantum Company, Through Merger with Real Asset Acquisition Corp.23.2.2026 13:49:00 CET | Press release
Global commercial leader with 21 systems sold to 13 customers to date – including 4 out of the top 10 supercomputing centres globally. Industrial leader with 15 systems delivered (largest number publicly disclosed by selected quantum companies1), 30+ computers built, own chip factory and quantum data centre. The transaction values IQM at a pre-money equity valuation of approximately USD 1.8 billion and makes IQM the first European quantum company to go public. With the close of this transaction, IQM’s cash position expected to exceed USD 450 million.2 Significant business momentum, with at least USD 35 million3 2025 revenue (unaudited) and over USD 100 million bookings / visibility as of year-end 2025. Strong commercial integrations with high-performance computing and enterprise platforms across the quantum/AI value chain such as NVIDIA, Hewlett Packard Enterprise, AWS, Toyo Corporation and Bechtle AG. Technical successes, achieving greater than 99.9% fidelity for single-qubit and two-
Organon Enters into Agreement to License MIUDELLA®, Sebela Pharmaceuticals’ Hormone-Free Intrauterine Device23.2.2026 13:30:00 CET | Press release
MIUDELLA® is a strategic addition to Organon’s portfolio, strengthening its long‑term commitment to advancing women’s health Organon (NYSE: OGN), a global healthcare company with a mission to deliver impactful medicines and solutions for a healthier every day, announced today that it has entered into an agreement to exclusively license global rights to MIUDELLA, Sebela Pharmaceuticals’ hormone-free copper intrauterine device (IUD) contraceptive. The effectiveness of this transaction is subject to review under the Hart-Scott-Rodino Antitrust Improvements Act and to U.S. Food and Drug Administration (FDA) approval of MIUDELLA's alternate supply chain entities and certain other conditions. MIUDELLA, the first hormone-free copper IUD approved in the U.S. in the last 40 years, is complementary to Organon’s commercial capabilities and would further Organon’s commitment to building a portfolio of products that meet women’s diverse reproductive health needs. MIUDELLA was approved by the FDA on
Lenovo Unlocks Data Potential with Next Generation of AI-Driven ThinkEdge Solutions23.2.2026 12:00:00 CET | Press release
New ThinkEdge devices deliver scalable, rugged, and versatile intelligence from gateway to high-performance edge for real-time insights Lenovo™ expanded its ThinkEdge portfolio with a new generation of AI-driven edge computing solutions, including the compact and reliable ThinkEdge SE10n Gen 2, the AI-ready ThinkEdge SE30n Gen 2, the AI-powerhouse ThinkEdge SE60n Gen 2, and Lenovo’s first industrial all-in-one (AIO) Panel PC, the ThinkEdge SE50a. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260223166717/en/ ThinkEdge SE10n Gen 2 As enterprises push intelligence closer to operations to improve resilience, reduce latency, and keep sensitive data local, edge computing has become a critical layer between devices, infrastructure, and cloud. Lenovo’s ThinkEdge solutions are purpose-built, industrial-grade edge systems designed to run reliably in harsh, space-constrained environments where traditional servers or PCs are impractic
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom